rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2011-7-3-391-393rpcardio-815Research ArticleFORUMSФОРУМЫTHE NEWS FROM RECENT CONGRESS OF AMERICAN COLLEGE OF CARDIOLOGY (NEW ORLEANS, APRIL 2-5, 2011)НОВОСТИ ПОСЛЕДНЕГО КОНГРЕССА АМЕРИКАНСКОЙ КОЛЛЕГИИ КАРДИОЛОГИИ (НОВЫЙ ОРЛЕАН, 2-5 АПРЕЛЯ 2011 Г.)МарцевичС. Ю.MartsevichS. Yu.

д.м.н., профессор, руководитель отдела профилактической фармакотерапии ГНИЦ ПМ; профессор кафедры доказательной медицины Первого МГМУ им. И.М. Сеченова

smartsevich@gnicpm.ruКутишенкоН. П.KutishenkoN. P.

д.м.н., руководитель лаборатории отдела профилактической фармакотерапии

ДроздоваЛ. Ю.DrozdovaL. Y.

м.н.с. отдела профилактической фармакотерапии

Государственный научно-исследовательский центр профилактической медицины Первый московский медицинский университет им. И.М. СеченоваRussian FederationГосударственный научно-исследовательский центр профилактической медициныRussian Federation20111701201673391393Copyright © Martsevich S.Y., Kutishenko N.P., Drozdova L.Y., 20162016Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю.Martsevich S.Y., Kutishenko N.P., Drozdova L.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/815

.

ReferencesOgawa H., Kim-Mitsuyama S., Jinnouchi T. et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32(7):575-80.Ogawa H., Kim-Mitsuyama S., Jinnouchi T. et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res 2009;32(7):575-80.Matsushita K., Muramatsu T., Kondo T. et al; NAGOYA HEART Study Group. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. J Cardiol 2010;56(1):111-7.Matsushita K., Muramatsu T., Kondo T. et al; NAGOYA HEART Study Group. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. J Cardiol 2010;56(1):111-7.Strauss M.H., Hall A.S. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2010;31(2):261-2.Strauss M.H., Hall A.S. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2010;31(2):261-2.Park K.W., Yoon J.H., Kim J.S. et al. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am Heart J. 2009 May;157(5):811-817.Park K.W., Yoon J.H., Kim J.S. et al. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am Heart J. 2009 May;157(5):811-817.Trial watch. DAPT study. Harv Heart Lett 2010;20(5):7.Trial watch. DAPT study. Harv Heart Lett 2010;20(5):7.Cohen A.T., Spiro T.E., Büller H.R. et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011 Feb 27 [Epub ahead of print].Cohen A.T., Spiro T.E., Büller H.R. et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011 Feb 27 [Epub ahead of print].Durand-Zaleski I., Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22 Suppl 4:19-27.Durand-Zaleski I., Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22 Suppl 4:19-27.Maron D.J., Boden W.E., Weintraub W.S. et al. Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use? Curr Treat Options Cardiovasc Med 2011;13(1):16-25.Maron D.J., Boden W.E., Weintraub W.S. et al. Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use? Curr Treat Options Cardiovasc Med 2011;13(1):16-25.George J.C., Varghese V., Dangas G., Popma J.J. Transcatheter aortic valve implantation: lessons from the PARTNER (Placement of Aortic Transcatheter Valves) trial. JACC Cardiovasc Interv 2011;4(1): 132-3.George J.C., Varghese V., Dangas G., Popma J.J. Transcatheter aortic valve implantation: lessons from the PARTNER (Placement of Aortic Transcatheter Valves) trial. JACC Cardiovasc Interv 2011;4(1): 132-3.

The authors declare that there are no conflicts of interest present.